Alirocumab

Alirocumab is an injectable cholesterol drug that lowers LDL by roughly half to 60% on top of a statin, far more than any pill can, by blocking a protein called PCSK9. Most people end up on it because their LDL is still too high despite a statin (often plus

Ezetimibe) and they need a much bigger lever, or they genuinely can't tolerate statins and need strong LDL lowering without them. It's also used for inherited high cholesterol (familial hypercholesterolemia), where LDL runs high from birth. It's sold as Praluent, given as a self-injection every two weeks or once a month.

This is one of the few lipid drugs with hard outcome data behind it, not just a number on a lab report. In people who recently had a heart attack or unstable angina, it cuts the risk of further heart attacks and strokes, and it's one of the only LDL-lowering drugs of its kind to also show a reduction in death from any cause. You won't feel anything taking it, the effect is entirely on your bloodwork and your long-term risk, and it's well tolerated. The main practical downsides are that it's an injection and it's expensive.

Deep-dive

PCSK9 is a protein your liver makes that acts like a wrecking crew for LDL receptors. LDL receptors sit on the surface of liver cells and pull LDL particles out of your blood. Normally a receptor grabs an LDL particle, drags it inside, drops it off, and goes back to the surface to do it again. PCSK9 interrupts that recycling: it binds the receptor and marks it for destruction, so instead of being reused, the receptor gets broken down. Fewer receptors means less LDL cleared from the blood. Alirocumab is a monoclonal antibody that binds circulating PCSK9 and takes it out of action, so LDL receptors survive longer, recycle more, and clear far more LDL. It reaches the same endpoint as a statin, more working LDL receptors on the liver, but by a different route, which is why it stacks cleanly on top of statin therapy.

The magnitude is the headline. As monotherapy, alirocumab 75 mg every two weeks lowers LDL by around 47%, and on top of a statin the higher 150 mg dose pushes reductions toward 60%. It also produces meaningful drops in ApoB and non-HDL cholesterol, a modest reduction in lipoprotein(a), a small triglyceride reduction, and a slight rise in HDL. In people with inherited high cholesterol the phase 2 data showed reductions of up to roughly 68%, and the effect holds steady over years of use with no tachyphylaxis, the body doesn't adapt around it.

Does it actually prevent events? This is the question that matters, because a drug can move a lab number without changing anything that happens to you. The ODYSSEY OUTCOMES trial settled it: 18,924 people who had an acute coronary syndrome (a heart attack or unstable angina) 1 to 12 months earlier, already on high-intensity or maximum-tolerated statins, randomized to alirocumab or placebo and followed a median of 2.8 years. The alirocumab dose was titrated to keep LDL in a target range of 25 to 50 mg/dL. It cut the primary composite endpoint of coronary heart disease death, heart attack, ischemic stroke, and hospitalization for unstable angina by 15%. The absolute risk reduction was about 1.6 percentage points, and the benefit was larger in people who started with higher LDL.

The mortality signal. Here is where alirocumab stands slightly apart from evolocumab, its sibling PCSK9 drug. In ODYSSEY OUTCOMES, fewer people died in the alirocumab group, 3.5% versus 4.1% on placebo, a reduction in all-cause death that was statistically significant. PCSK9 inhibitor trials had generally not shown a death benefit before this, and the effect here was concentrated in people with higher baseline LDL and longer follow-up. It's worth being honest about the nuance: this was driven more by the size and length of the trial than by alirocumab being fundamentally different from evolocumab, and the absolute difference is small. But it's a real finding and it's part of why this drug is taken seriously.

Total events, not just the first one. Looking only at first events undersells these drugs, because high-risk people have repeat events. A prespecified analysis of total events found alirocumab prevented roughly twice as many total nonfatal cardiovascular events and deaths as first events alone, which is a more complete picture of what the drug does over time.

Women. Women made up about 25% of ODYSSEY OUTCOMES, 4,762 of the participants. A prespecified analysis by sex found women started with higher baseline LDL and higher lipoprotein(a) than men, and that alirocumab improved cardiovascular outcomes irrespective of sex, with no meaningful difference in the relative benefit. One practically useful finding from that analysis: the reduction in total cardiovascular events was greater in people with higher baseline lipoprotein(a), and since women in the trial carried higher Lp(a) on average, this matters for them specifically. The LDL lowering itself is no different by sex, and no dose adjustment is needed. The broader practical point is that women are consistently undertreated for cholesterol and more likely to come off statins citing side effects, so a drug that works equally well and is easy to tolerate helps close that gap. Alirocumab is not used in pregnancy or breastfeeding, lipid-lowering drugs are generally paused during this period and there's no adequate human safety data.

Older adults. A prespecified analysis by age found alirocumab improved outcomes regardless of age, and because older patients start at higher absolute risk, the absolute benefit actually increased with advancing age while the harms did not. Because alirocumab doesn't carry the muscle-symptom and drug-interaction baggage that high-intensity statins do, it's a sensible way to reach LDL targets in older people without escalating statin dose. No dose adjustment for age.

Kidney function. A prespecified renal analysis found alirocumab reduced events across the range of kidney function studied, with the clearest relative benefit in people with eGFR above 60. People with severe kidney impairment (eGFR below 30) were excluded from the trial, so the drug is less well characterized there, but no dose adjustment is recommended for mild to moderate impairment.

The diabetes question. Statins carry a small, real signal for new-onset diabetes, so this was checked carefully for PCSK9 inhibitors. In ODYSSEY OUTCOMES, alirocumab did not increase new-onset diabetes or worsen glycemic control, and people who already had diabetes got a larger absolute benefit because their baseline risk was higher. The honest asterisk: Mendelian randomization studies, which look at people with naturally low PCSK9 from genetics, suggest a small increased diabetes risk, and a later post-hoc analysis explored how LDL and Lp(a) changes relate to incident diabetes. The trial evidence is reassuring; the genetic data is a mild caveat that longer follow-up can't fully rule out.

Familial hypercholesterolemia. Beyond the post-heart-attack population, alirocumab is used for inherited high cholesterol. The ODYSSEY HIGH FH study tested 150 mg every two weeks in people with heterozygous familial hypercholesterolemia whose LDL stayed at or above 160 mg/dL despite maximally tolerated statins, and showed substantial further lowering. An open-label extension of the FH program followed these patients longer and found the safety profile and LDL reductions held up. It's also approved for children aged 8 and older with this condition, which is unusual for a lipid drug and reflects how hard FH is to control with statins alone.

Long-term data. A long-term analysis from ODYSSEY OUTCOMES of the 8,242 patients eligible for 3 to 5 years of placebo-controlled follow-up found alirocumab remained safe and well tolerated over that span, with no new safety signals emerging. The practical read is that this is a drug you stay on indefinitely, the way statin users do.

Limitations of the evidence. The big outcome trial was funded by the manufacturers, which is normal for drugs at this stage but worth noting. The hard endpoint data comes from one specific population, people 1 to 12 months after an acute coronary syndrome, so the strongest evidence is for secondary prevention in that setting. There's no large outcome trial in genuinely low-risk people, and there shouldn't be, the absolute benefit there would be tiny. Severe kidney impairment is understudied. And the practical limitation outside the science is cost and access, this is an expensive biologic and insurance coverage often gates who actually gets it.

Dosage:

Two starting options: 75 mg every 2 weeks, or 300 mg once monthly (given as two 150 mg injections). The 75 mg dose is enough for most people, in the phase 3 program around three quarters reached their LDL target on it. If LDL is still too high after about 8 weeks, the dose goes up to 150 mg every 2 weeks, which is also the standard starting dose for inherited high cholesterol where a bigger drop is needed from the outset

Given as a subcutaneous self-injection, into the abdomen, thigh, or back of the upper arm. It comes as a prefilled pen or syringe

Rotate injection sites and don't inject into skin that's bruised, red, tender, or hard. Let the pen warm to room temperature before injecting, it stings less and is more comfortable

alirocumabIt's almost always an add-on, not a replacement. Keep your statin (and ezetimibe, if you're on it) going, stacks on top. The exception is genuine statin intolerance, where it's used without a statin

Give it 4-8 weeks before checking a lipid panel. The LDL effect shows up fast but you want a stable read before deciding whether to up-titrate. The 8-week check is the standard decision point for moving from 75 mg to 150 mg

Same dose regardless of sex, age, body weight, or mild-to-moderate kidney or liver function. No adjustment needed. It is approved down to age 8 for inherited high cholesterol, which is rare for a lipid drug

Storage matters: it's a biologic, keep it refrigerated. It can sit at room temperature but only for a limited window, then it has to be discarded

This is a long-term drug. LDL returns to baseline within weeks of stopping, the same way it does with statins, so it's only worth taking if you plan to stay on it

Here's what you can expect:

You will not feel anything. Alirocumab has no perceptible day-to-day effect, no energy change, nothing you'd notice. The only evidence it's working is a blood test, and on that test the change is dramatic: LDL down by roughly half to 60%, showing up within the first few weeks and stable from then on.

The thing you might notice is at the injection site, mild redness, an itch, or tenderness for a day or so. It's the most common real effect and usually fades as you get used to the technique.

Everything else is invisible and long-term: a lower heart attack and stroke risk that compounds the longer you stay on it. This is a number-mover and a risk-mover, not something you experience.

Side effects & risks:

It's well tolerated. Across the large trials the overall adverse event profile was close to placebo, and crucially, it does not cause the muscle symptoms that drive people off statins

Injection site reactions are the most common real complaint, redness, itching, tenderness, occasionally mild swelling. Usually minor, usually settle with site rotation and good technique. This was the one adverse event consistently higher than placebo in the trials

Flu-like symptoms, headache, and nasopharyngitis-type complaints show up occasionally, generally mild and not clearly above placebo rates

Allergic reactions are uncommon but possible with any injectable antibody. Most are minor (itching, rash, hives), but serious hypersensitivity reactions including angioedema and hypersensitivity vasculitis have been reported rarely. Stop and seek care if you get a serious reaction, and don't use it again if you've had one

Neurocognitive events such as memory impairment or confusion have been reported, but they are rare and the prospective evidence has not established a clear causal link. This was a theoretical concern raised because the drug pushes LDL very low, and so far the data is broadly reassuring

Diabetes: the trial data shows no increase in new-onset diabetes or worsening glucose control. Genetic (Mendelian randomization) data hints at a small possible effect, so it's reasonable to keep an eye on glucose if you're prediabetic, but the clinical evidence is reassuring

Very low LDL: alirocumab routinely produces LDL levels below anything seen with statins alone. The outcome and safety data at these levels is reassuring so far, but it's a relatively new place for medicine to be and very long-term data is still accumulating

Anti-drug antibodies can form against any biologic, detected in a small percentage of people. Neutralizing antibodies that would blunt the drug's effect are uncommon and have not been a major clinical problem

No significant drug interactions. As an antibody it's cleared differently from small-molecule drugs and doesn't tangle with the CYP450 system, so it doesn't interfere with other medications

Pregnancy and breastfeeding: not used. No adequate human data, and lipid-lowering therapy is generally paused during this period

Severe kidney or liver impairment: not well studied, since these patients were excluded from the major trials

🩸

Blood markers

Full lipid panel (LDL, HDL, triglycerides, total cholesterol), baseline and again at 4-8 weeks. This is the only way to confirm alirocumab is working, since you won't feel it, and the 8-week result is the decision point for whether to move from 75 mg to 150 mg. ApoB and non-HDL cholesterol are better markers than LDL alone if you can get them, they track the actual atherogenic particle burden, and lipoprotein(a) is worth measuring once at baseline since alirocumab lowers it modestly and the trial data showed bigger benefit in people with higher Lp(a).

HbA1c or fasting glucose, baseline. Not because alirocumab clearly raises glucose, the trial data says it doesn't, but a baseline is sensible if you're prediabetic or diabetic, given the residual uncertainty from genetic studies.

Liver enzymes (ALT, AST), baseline. Mostly relevant because of the background statin rather than alirocumab itself, but a baseline is standard before starting combination lipid therapy.

Recheck the lipid panel periodically once stable, every 6-12 months, to confirm you're holding target. No specialized monitoring schedule beyond that, alirocumab doesn't require the CK, copper, or other targeted bloodwork some compounds do.

Who actually needs what: anyone starting alirocumab should get a baseline lipid panel (ideally with ApoB and a one-time Lp(a)) and have it rechecked at 4-8 weeks, that's the core. Liver enzymes and glucose at baseline are sensible but low-effort. If you're statin-intolerant and on alirocumab as monotherapy, the lipid panel is essentially the whole monitoring picture.

Alirocumab is a prescription medication.